Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, 419 Fangxie Road, Shanghai, 200011, China.
Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, 413 Zhaozhou Road, Shanghai, 200011, China.
BMC Womens Health. 2022 Sep 16;22(1):377. doi: 10.1186/s12905-022-01971-z.
Considering the unique biological behavior of cervical adenocarcinoma (AC) compared to squamous cell carcinoma, we now lack a distinct method to assess prognosis for AC patients, especially for intermediate-risk patients. Thus, we sought to establish a Silva-based model to predict recurrence specific for the intermediate-risk AC patients and guide adjuvant therapy.
345 AC patients were classified according to Silva pattern, their clinicopathological data and survival outcomes were assessed. Among them, 254 patients with only intermediate-risk factors were identified. The significant cutoff values of four factors (tumor size, lymphovascular space invasion (LVSI), depth of stromal invasion (DSI) and Silva pattern) were determined by univariate and multivariate Cox analyses. Subsequently, a series of four-, three- and two-factor Silva-based models were developed via various combinations of the above factors.
(1) We confirmed the prognostic value of Silva pattern using a cohort of 345 AC patients. (2) We established Silva-based models with potential recurrence prediction value in 254 intermediate-risk AC patients, including 12 four-factor models, 30 three-factor models and 16 two-factor models. (3) Notably, the four-factor model, which includes any three of four intermediate-risk factors (Silva C, ≥ 3 cm, DSI > 2/3, and > mild LVSI), exhibited the best recurrence prediction performance and surpassed the Sedlis criteria.
Our study established a Silva-based four-factor model specific for intermediate-risk AC patients, which has superior recurrence prediction performance than Sedlis criteria and may better guide postoperative adjuvant therapy.
考虑到宫颈腺癌(AC)与鳞状细胞癌相比具有独特的生物学行为,我们目前缺乏一种明确的方法来评估 AC 患者的预后,尤其是中危患者。因此,我们试图建立一个基于 Silva 的模型,以预测特定于中危 AC 患者的复发,并指导辅助治疗。
根据 Silva 模式对 345 例 AC 患者进行分类,评估其临床病理数据和生存结局。其中,确定了 254 例仅有中危因素的患者。通过单因素和多因素 Cox 分析确定了四个因素(肿瘤大小、脉管间隙浸润(LVSI)、间质浸润深度(DSI)和 Silva 模式)的显著截断值。随后,通过上述因素的各种组合,开发了一系列四因素、三因素和两因素 Silva 模型。
(1)我们通过 345 例 AC 患者的队列证实了 Silva 模式的预后价值。(2)我们在 254 例中危 AC 患者中建立了具有潜在复发预测价值的 Silva 模型,包括 12 个四因素模型、30 个三因素模型和 16 个两因素模型。(3)值得注意的是,包括 Silva C、≥3cm、DSI>2/3 和>轻度 LVSI 等四个中间风险因素中的任意三个的四因素模型,具有最佳的复发预测性能,超过了 Sedlis 标准。
我们的研究建立了一个针对中危 AC 患者的基于 Silva 的四因素模型,其复发预测性能优于 Sedlis 标准,可能更好地指导术后辅助治疗。